Vijoice (Alpelisib) Patent Expiration, LOE Window & CMS Spending
Vijoice (Alpelisib) by Novartis: FDA Orange Book core substance LOE 2033-04-29 (last listed 2037-02-17), 0 AB generics, $90.9M 2024 CMS Part D & Medicaid spend, and $32,500 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Novartis |
| FDA Application & Pathway | N215039 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2033-04-29 |
| Last Listed Patent or Exclusivity Date | 2037-02-17 |
| Orange Book Patents (*PED Extensions) | 4 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $90.9M |
| 2024 Medicare Part D Spend | $8.5M |
| 2024 Medicaid Spend | $82.4M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($32,500 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.